Mini-Nucleosome Core Proteins for Targeted Nucleic Acid Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current AAV vectors face limitations such as payload size restrictions, site-non-specific integration, pre-existing neutralizing antibodies, high antibody production, toxicity from high doses, and inability to target multiple organs effectively, as well as inefficiencies in non-viral vectors like low transfection efficiency and stability in body fluids.
Innovation Solution
Development of mini-nucleosome core proteins with a nucleic acid binding domain, targeting domain, and optional stability and release domains to facilitate targeted, stable, and efficient delivery of nucleic acids to specific cell types, overcoming the limitations of AAV and prior non-viral vectors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If AAV vectors are used for gene delivery, then transduction efficiency is improved, but payload size is limited to 4.5 kb
Solution Approach 1:
The invention segments the gene delivery system into multiple components: a capsid protein for viral-like delivery, a separate large T antigen for replication function, and modular genetic elements (promoter, ITRs, transgene). This segmentation allows the delivery vehicle to accommodate larger genetic payloads while maintaining efficient transduction, overcoming the 4.5 kb limit of conventional AAV vectors.
2Productivity
If AAV vectors are used for gene delivery, then delivery capability is improved, but site-specific integration is poor
Solution Approach 1:
The invention introduces a specific integration mediator mechanism where the capsid protein and large T antigen work together to mediate site-specific integration into AAVS1 or other safe harbor loci. This intermediary mechanism ensures precise genomic integration rather than random insertion, addressing the safety concern while maintaining delivery efficiency.
3Productivity
If high doses of AAV are administered, then transduction efficiency is improved, but toxicity increases
Solution Approach 1:
The invention changes key parameters of the delivery system by using a recombinant capsid protein with optimized amino acid sequences that enhance transduction efficiency at lower doses. The modified capsid structure and composition allow effective gene delivery at reduced concentrations, thereby minimizing toxicity while maintaining high transduction efficiency.
4Productivity
If AAV vectors are used for gene delivery, then initial treatment efficacy is improved, but repeat treatment capability is reduced due to antibody formation
Solution Approach 1:
The invention creates a dynamic delivery system where the recombinant capsid protein can be easily modified to produce different serotypes or variants. This dynamic capability allows the system to adapt to neutralizing antibodies from previous treatments by switching to alternative capsid configurations, thereby maintaining repeat treatment effectiveness while preserving initial treatment efficacy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The mini-nucleosome core proteins provide enhanced stability, cell-type specificity, and prolonged expression by slow nucleic acid release, enabling effective gene therapy for conditions like Huntington's, Stargardt, and Duchenne muscular dystrophy without immunogenicity or toxicity.
Implementation Method 1
polypeptides that are capable of associating with nucleic acid molecules
Data Source
AI summary
The present disclosure provides compositions and methods relating to mini-nucleosome core proteins and/or delivery of nucleic acids. In particular, the present disclosure includes, among other things, non-viral proteinaceous vehicles for delivery of nucleic acids. In various embodiments, non-viral proteinaceous vehicles provided herein include (a) a nucleic acid binding domain; (b) a targeting domain; and, optionally, (c) a nucleic acid release domain, stability domain, and/or an oligomerization domain, and/or a linker domain.